Brief: Xbiotech-Developed Covid-19 Test Supports Convalescent Blood Treatments Now Approved Under FDA Emergency Use Authorization
24/08/2020 13:26
Aug 24 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH-DEVELOPED COVID-19 TEST SUPPORTS CONVALESCENT
BLOOD
TREATMENTS NOW APPROVED UNDER FDA EMERGENCY USE AUTHORIZATION
* XBIOTECH INC - BIOBRIDGE GLOBAL WILL BE USING XBIOTECH'S
COVID-19 ANTIBODY TEST TO IDENTIFY CONVALESCENT BLOOD PRODUCTS
Source text for Eikon: ID:nGNX91Bwhm
Further company coverage: XBIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke